Rafael Correa-Rocha
Chief Scientific Officer ThyTech
Rafael Correa, Ph.D., M.D. is the Founding Director and Chief Scientific Officer THYTECH. His pioneering work focuses on immune tolerance and cell-based therapies, including the development of thyTreg therapy to prevent organ transplant rejection in infants. With over 15 years of research leadership in immunology and translational medicine, Dr. Correa has advanced cutting-edge therapies from bench to clinic and secured international recognition. He holds doctorates in Medicine and Biology from Universidad Autónoma and Universidad Complutense de Madrid.
Seminars
Wednesday 25th March 2026
NEW DATA: Keynote Presentation: Uncovering Clinical Advances with thyTregs™ to Expand the Frontiers of Treg Therapy
9:30 am
- Unveiling clinical data on Thytech’s thyTregs™ therapy preventing transplant rejection in heart transplant children
- Exploring thymic-derived allogeneic Treg therapeutic potential across multiple
- indications including Chron’s disease
- Discussing the escalation capacity of thyTregs™ to accelerate therapeutic success
